Related Experiment Video
Updated: Jun 13, 2025
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Multimodal gene and targeted drug therapy for chronic myelogenous leukemia: Computational target analysis and
Abstract:
Developing an efficient and safe therapy necessitates a mechanistic understanding of the complex underlying pathology and manipulation of the multiple pathways at the molecular and genetic level. Network-based simulation of chronic myeloid leukemia (CML), a relatively well-understood cancer model, revealed the dynamics of simultaneously expressing pro-apoptotic BIM and silencing pro-survival MCL-1 in combination with the BCR-ABL-targeted tyrosine kinase inhibitor dasatinib. Viral/nonviral chimeric nanoparticles (ChNPs) composed of a BIM-expressing adeno-associated virus (AAV) core and a degradable polymeric shell that encapsulates MCL-1 siRNA (BIM/MCL-1 ChNPs) synergistically and selectively killed BCR-ABL+ CML cells in combination with dasatinib. In a mouse CML model, the BIM/MCL-1 ChNPs and dasatinib combination therapy suppressed proliferation of BCR-ABL+ hematopoietic cells and prevented leukemic infiltration of organs. The synergistic anti-leukemic effect was further pronounced in an acute phase model of the disease. This study investigated a strategy of developing a versatile and tunable multimodal therapy assisted by a computational toolset that analyzes the molecular foundation of a disease and predicts therapeutic response. The interdisciplinary approach developed and validated in this study can be used in discovering new therapies for cancer and other diseases.
Insights
This study developed novel chimeric nanoparticles (ChNPs) delivering BIM and MCL-1 siRNA. These nanoparticles synergize with dasatinib to effectively treat chronic myeloid leukemia (CML) in preclinical models.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Chronic myeloid leukemia (CML) requires mechanistic understanding for effective therapy.
- Targeting pro-apoptotic BIM and pro-survival MCL-1 pathways is crucial.
- Dasatinib is a BCR-ABL-targeted tyrosine kinase inhibitor used in CML treatment.
Purpose of the Study:
- To develop a multimodal therapy for CML using computational tools.
- To investigate synergistic effects of BIM/MCL-1 chimeric nanoparticles (ChNPs) with dasatinib.
- To validate a versatile and tunable therapeutic strategy for cancer treatment.
Main Methods:
- Network-based simulation to understand CML dynamics.
- Development of viral/nonviral chimeric nanoparticles (ChNPs) encapsulating BIM-expressing adeno-associated virus (AAV) and MCL-1 siRNA.
- Combination therapy of BIM/MCL-1 ChNPs and dasatinib in a mouse CML model.
Main Results:
- BIM/MCL-1 ChNPs synergistically and selectively killed BCR-ABL+ CML cells with dasatinib.
- Combination therapy suppressed proliferation of BCR-ABL+ hematopoietic cells in vivo.
- Leukemic organ infiltration was prevented, with enhanced effects in acute phase models.
Conclusions:
- An interdisciplinary approach combining computational tools and nanomedicine can identify effective cancer therapies.
- The developed BIM/MCL-1 ChNPs offer a promising synergistic strategy for CML treatment.
- This validated approach can be applied to discover novel therapies for various diseases.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...